GlaxoSmithKline launched a $50 million strategic venture capital fund to further the development of so-called bioelectronics or electroceuticals, which use electrical impulses rather than chemicals or biological molecules to treat disease. Ultimately, nanoscale implants could be developed to encourage insulin production, correct muscle imbalances or regulate food consumption, for example.
GSK launches $50M bioelectronics venture fund
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan
|Assistant Vice President - Dental Director||
|Vice President of Finance||
Urban Health Plan, Inc.